There were three retrospective cohort studies [7, 29, 42], and eight prospective cohort studies [3–6, 8, 10, 17, 39], and the frequency of KIT mutations in CBF-AML varied from 16–46% [8, 16], with 12–46% [3, 8] and 9–53% [5, 9] in the t(8,21) and inv(16) AML subgroups, respectively. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.